CRH Medical Corp.

CRH-T

Analysis and Opinions about CRH-T

Signal
Opinion
Expert
PARTIAL BUY
PARTIAL BUY
April 11, 2017

He likes this. A bit of a rollup. They are buying portions of medical practices in the US, and then are installing anaesthesiologists to do anaesthetic services. The valuation is running up a bit, but if you are looking at Enterprise Value to a bit of multiple, it is about 16X. Still a bit pricey, but nothing too crazy. He likes that they are offering liquidity to doctors, who are starting to age and want to get some cash out of the business. Good insider ownership. Worth owning, but you might want to average into it.

He likes this. A bit of a rollup. They are buying portions of medical practices in the US, and then are installing anaesthesiologists to do anaesthetic services. The valuation is running up a bit, but if you are looking at Enterprise Value to a bit of multiple, it is about 16X. Still a bit pricey, but nothing too crazy. He likes that they are offering liquidity to doctors, who are starting to age and want to get some cash out of the business. Good insider ownership. Worth owning, but you might want to average into it.

Ryan Modesto
Managing Partner, 5i Research
Price
$12.030
Owned
No
BUY
BUY
April 3, 2017

It is your classic breakout. It is just pulling back now and then will continue back up. It is a very bullish chart.

It is your classic breakout. It is just pulling back now and then will continue back up. It is a very bullish chart.

Keith Richards
Portfolio Manager, ValueTrend Wealth Management
Price
$10.920
Owned
Unknown
COMMENT
COMMENT
March 13, 2017

A very strong company. ROC is astoundingly high. The valuation looks really good. From a pure, financial Return on Capital and valuation perspective, this looks really good.

A very strong company. ROC is astoundingly high. The valuation looks really good. From a pure, financial Return on Capital and valuation perspective, this looks really good.

Matt Kacur
President, FSA Financial Science and Art
Price
$10.720
Owned
Unknown
BUY WEAKNESS
BUY WEAKNESS
March 10, 2017

Doesn’t think they will need to do an equity raise unless they do a big acquisition. They roughly have the cash flow they need to make an acquisition each quarter, of about the same size that they have been doing. His one caution is that the valuation is very high. Be prepared that an analyst could come out and say it is fully valued, resulting in the stock pulling back. If it did, it would probably be a great buying opportunity. Also, if they did an equity offering, that would be another great time to add to your holdings.

Doesn’t think they will need to do an equity raise unless they do a big acquisition. They roughly have the cash flow they need to make an acquisition each quarter, of about the same size that they have been doing. His one caution is that the valuation is very high. Be prepared that an analyst could come out and say it is fully valued, resulting in the stock pulling back. If it did, it would probably be a great buying opportunity. Also, if they did an equity offering, that would be another great time to add to your holdings.

Bruce Campbell (2)
President & Portfolio Manager, Stone Castle Investment Management Inc.
Price
$10.380
Owned
Unknown
HOLD
HOLD
February 28, 2017

Involved with gastrointestinal, and they work with anesthesia to provide for colonoscopies, etc. They’ve been trying to consolidate the market. Just reported a blowout quarter and the stock moved up quite a bit. Management has done a great job of under promising and over delivering.

CRH Medical Corp. (CRH-T)
February 28, 2017

Involved with gastrointestinal, and they work with anesthesia to provide for colonoscopies, etc. They’ve been trying to consolidate the market. Just reported a blowout quarter and the stock moved up quite a bit. Management has done a great job of under promising and over delivering.

Peter Imhof
Vice President & Portfolio Manager, AGF Investments Inc
Price
$9.190
Owned
Yes
HOLD
HOLD
February 22, 2017

This tends to be a serial acquirer, and he generally doesn’t like these. However, in this case he likes management and feels they are very competent.

CRH Medical Corp. (CRH-T)
February 22, 2017

This tends to be a serial acquirer, and he generally doesn’t like these. However, in this case he likes management and feels they are very competent.

Jerome Hass
Portfolio Manager, Lightwater Partners
Price
$8.570
Owned
No
BUY
BUY
January 24, 2017

Has done tremendously well. Broke out of a trading range at about $5.50 on heavy volume. It has a high cash ROE and a relatively low P/E ratio. Feels they are getting to be more well known, but they don’t have a wide analyst following, which he would like to see. Expects the stock price to consolidate at around the $7.50-$8.50 level. Assuming they can continue to grow their earnings and add more facilities to their portfolio, the stock certainly has room to run. Represents decent value at these levels.

CRH Medical Corp. (CRH-T)
January 24, 2017

Has done tremendously well. Broke out of a trading range at about $5.50 on heavy volume. It has a high cash ROE and a relatively low P/E ratio. Feels they are getting to be more well known, but they don’t have a wide analyst following, which he would like to see. Expects the stock price to consolidate at around the $7.50-$8.50 level. Assuming they can continue to grow their earnings and add more facilities to their portfolio, the stock certainly has room to run. Represents decent value at these levels.

Jason Del Vicario
Portfolio Manager, HollisWealth
Price
$7.990
Owned
Yes
BUY
BUY
January 6, 2017

ROC on this is tremendous. He has it as 104%, which is almost unheard of. Also, it looks undervalued.

ROC on this is tremendous. He has it as 104%, which is almost unheard of. Also, it looks undervalued.

Matt Kacur
President, FSA Financial Science and Art
Price
$7.810
Owned
Unknown
COMMENT
COMMENT
January 3, 2017

Technically, this looks fantastic. On any medical type stocks, you go with the wave. Right now the wave is up, and if he had to Buy or Sell it, he would buy.

Technically, this looks fantastic. On any medical type stocks, you go with the wave. Right now the wave is up, and if he had to Buy or Sell it, he would buy.

Elliott Fishman
Director of U.S. and international equity trading, Trading Services Group, Scotia Wealth
Price
$7.250
Owned
Unknown
BUY
BUY
December 20, 2016

It is a buy or a hold. He is one of the largest holders. This has been a top pick of his. It is a health care company, the top performing one in Canada this year. They did a very good job at increasing their earnings. Last quarter the stock took off. A lot more small cap managers are looking at it now. He likes the management team from a previous company.

CRH Medical Corp. (CRH-T)
December 20, 2016

It is a buy or a hold. He is one of the largest holders. This has been a top pick of his. It is a health care company, the top performing one in Canada this year. They did a very good job at increasing their earnings. Last quarter the stock took off. A lot more small cap managers are looking at it now. He likes the management team from a previous company.

Peter Imhof
Vice President & Portfolio Manager, AGF Investments Inc
Price
$7.060
Owned
Yes
SELL
SELL
December 5, 2016

A good little Canadian medical story. Operates primarily in the US, and has been rolling up some healthcare services. He is cautious in this area right now. The US health business is pretty complicated right now, as there are a bunch of pieces to it, unlike the Canadian system. One segment of this company has a fair bit of “off network” business, which pays much better than being paid by Medicare and Medicaid, but sometimes it is hard to get paid, as insurers take their time. Companies like this could be under a bit of pressure next year, so he would be cautious. At this point he wouldn’t be owning it.

CRH Medical Corp. (CRH-T)
December 5, 2016

A good little Canadian medical story. Operates primarily in the US, and has been rolling up some healthcare services. He is cautious in this area right now. The US health business is pretty complicated right now, as there are a bunch of pieces to it, unlike the Canadian system. One segment of this company has a fair bit of “off network” business, which pays much better than being paid by Medicare and Medicaid, but sometimes it is hard to get paid, as insurers take their time. Companies like this could be under a bit of pressure next year, so he would be cautious. At this point he wouldn’t be owning it.

Alex Ruus
Portfolio Manager, Arrow Capital Management
Price
$7.530
Owned
No
TOP PICK
TOP PICK
November 16, 2016

This continues to grow by acquisition. They have 2 different product lines, but the anaesthesiology side is where they are really starting to grow. Generating between $5-$6 million in cash flow per quarter, along with a line that allows them to continue to make acquisitions. They’ve been pretty disciplined about how they have done this. (Analysts’ price target is $7.52.)

CRH Medical Corp. (CRH-T)
November 16, 2016

This continues to grow by acquisition. They have 2 different product lines, but the anaesthesiology side is where they are really starting to grow. Generating between $5-$6 million in cash flow per quarter, along with a line that allows them to continue to make acquisitions. They’ve been pretty disciplined about how they have done this. (Analysts’ price target is $7.52.)

Bruce Campbell (2)
President & Portfolio Manager, Stone Castle Investment Management Inc.
Price
$7.390
Owned
Yes
COMMENT
COMMENT
October 26, 2016

The company is not going to be out raising money, but are going to be doing smaller tuck in acquisitions. They are in the acquisition business. If they have the cash flow to fund an acquisition, they will be fine, but if not and it is something bigger, they’ll probably have to go to the market.

CRH Medical Corp. (CRH-T)
October 26, 2016

The company is not going to be out raising money, but are going to be doing smaller tuck in acquisitions. They are in the acquisition business. If they have the cash flow to fund an acquisition, they will be fine, but if not and it is something bigger, they’ll probably have to go to the market.

Bruce Campbell (2)
President & Portfolio Manager, Stone Castle Investment Management Inc.
Price
$6.210
Owned
Yes
HOLD
HOLD
October 20, 2016

This has spent the last 18 months consolidating, and has just recently broke out of a trading range at around the $5.40-$5.50 level. He sees a lot of upside in this. A very well-run company. Their cash ROE is north of 30%, and their cash P/E ratio is at around 10 or 11.

CRH Medical Corp. (CRH-T)
October 20, 2016

This has spent the last 18 months consolidating, and has just recently broke out of a trading range at around the $5.40-$5.50 level. He sees a lot of upside in this. A very well-run company. Their cash ROE is north of 30%, and their cash P/E ratio is at around 10 or 11.

Jason Del Vicario
Portfolio Manager, HollisWealth
Price
$6.140
Owned
Yes
HOLD
HOLD
September 29, 2016

He really likes the management team. He continues to hold it although the whole healthcare sector has been under scrutiny. Their earnings have grown as they made tuck-in acquisitions. They recently did some marketing. Over the next couple of years earnings estimates should go up.

CRH Medical Corp. (CRH-T)
September 29, 2016

He really likes the management team. He continues to hold it although the whole healthcare sector has been under scrutiny. Their earnings have grown as they made tuck-in acquisitions. They recently did some marketing. Over the next couple of years earnings estimates should go up.

Peter Imhof
Vice President & Portfolio Manager, AGF Investments Inc
Price
$5.110
Owned
Yes
Showing 31 to 45 of 88 entries